Audentes Therapeutics, Inc., a wholly-owned subsidiary of Astellas, has issued a press release on August 20, 2020, to provide an update on the ASPIRO clinical trial evaluating AT132 in patients with X-linked Myotubular Myopathy (XLMTM), a serious, life-threatening neuromuscular disease characterized by extreme muscle weakness, respiratory failure, and early death.
(PR Link :https://www.audentestx.com/press-releases/)
Astellas and Audentes are deeply saddened by the loss of the patients and extend our deepest sympathies to the families during this time. We remain committed to the AT132 development program and the XLMTM patient community and are working closely with regulatory authorities to ensure our path forward continues to maximize the safety of all patients.
